Hema Ramkumar, MD
Retina Specialist · Fullerton, CANPI 1184919524
Payments from drug & device makers
Across 147 payments — averaging $1170.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$95K
- Alimera Sciences, Inc.$50K
- Genentech USA, Inc.$14K
- Eyepoint US, Inc.$6K
- Ocular Therapeutix, Inc.$3K
- Regeneron Healthcare Solutions, Inc.$848
- plus $3K from 17 others
Across 10 payments — averaging $270.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 16 | $94,716 |
| Alimera Sciences, Inc. | 15 | $50,036 |
| Genentech USA, Inc. | 22 | $14,298 |
| Eyepoint US, Inc. | 1 | $6,370 |
| Ocular Therapeutix, Inc. | 4 | $3,118 |
| Regeneron Healthcare Solutions, Inc. | 34 | $848 |
| ANI Pharmaceuticals, Inc. | 4 | $556 |
| AbbVie(2 entities) | 21 | $490 |
| Alcon | 3 | $401 |
| Apellis Pharmaceuticals, Inc. | 10 | $325 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $150 |
| Glaukos Corporation | 1 | $137 |
| Bausch & Lomb Americas Inc. | 2 | $135 |
| Rxsight Inc | 1 | $125 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Astellas Pharma US Inc | 2 | $60 |
| Genentech, Inc. | 2 | $60 |
| Medtronic | 1 | $54 |
| Astellas Pharma Global Development | 1 | $47 |
| Amgen | 2 | $32 |
| Biogen | 1 | $26 |
| Harrow Eye, LLC | 1 | $25 |
| Novartis | 1 | $23 |
How this compares
$172,100 in reported general payments places this provider in the 75th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Fullerton
- Ashkan PirouzFullerton$6.9M
- Sean AdreanFullerton$2.9M
- Dante PieramiciSanta Barbara$15.1M
- Margaret ChangSacramento$13.2M
- Hani Salehi-HadHuntington Beach$12.2M
- Payam AminiPasadena$9.9M
- Joel PearlmanSacramento$8.3M
- Dilsher DhootSanta Barbara$8.2M
- Roger GoldbergWalnut Creek$5M
- Nathan SteinleSanta Barbara$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.